Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Prostatic Neoplasms 1Neuroendocrine Tumors 1Gliosarcoma 1Glioblastoma 1Adenoma, Islet Cell 1

Interventions

Temozolomide 100Radiotherapy 49Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 22Bevacizumab 22Lomustine 16Nivolumab 14Surgical Procedures, Operative 10atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7fludarabine 6Radiotherapy, Intensity-Modulated 6Carboplatin 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Salts × 1 year × Clear all
NCT04216329 2026-01-23

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
11 enrolled 19 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡